HBC Fundamental Analysis - HOFSETH BIOCARE ASA

Name: HOFSETH BIOCARE ASA (HBC) Stock
Brand: HOFSETH BIOCARE ASA
Rating: 3 (3 reviews)

Fundamental Rating

Taking everything into account, HBC scores 1 out of 10 in our fundamental rating. HBC was compared to 76 industry peers in the Biotechnology industry. Both the profitability and financial health of HBC have multiple concerns. HBC has a expensive valuation and it also scores bad on growth.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year HBC has reported negative net income.

In the past year HBC has reported a negative cash flow from operations.

HBC had negative earnings in each of the past 5 years.

In the past 5 years HBC reported 4 times negative operating cash flow.

1.2 Ratios

HBC has a Return On Assets (-35.39%) which is comparable to the rest of the industry.

Looking at the Return On Equity, with a value of -13486.42%, HBC is doing worse than 72.37% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-35.39%
ROE	-13486.42%
ROIC	N/A

ROA(3y)-32.56%

ROA(5y)-30.06%

ROE(3y)-185.37%

ROE(5y)-136.87%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

HBC has a Gross Margin of 35.99%. This is comparable to the rest of the industry: HBC outperforms 48.68% of its industry peers.

In the last couple of years the Gross Margin of HBC has grown nicely.

HBC does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	35.99%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y128.49%

GM growth 5Y94.79%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

HBC does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, HBC has more shares outstanding

Compared to 5 years ago, HBC has more shares outstanding

The debt/assets ratio for HBC is higher compared to a year ago.

2.2 Solvency

Based on the Altman-Z score of 0.86, we must say that HBC is in the distress zone and has some risk of bankruptcy.

With a Altman-Z score value of 0.86, HBC perfoms like the industry average, outperforming 57.89% of the companies in the same industry.

HBC has a Debt/Equity ratio of 203.13. This is a high value indicating a heavy dependency on external financing.

The Debt to Equity ratio of HBC (203.13) is worse than 72.37% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	203.13
Debt/FCF	N/A
Altman-Z	0.86

ROIC/WACCN/A

WACC8.45%

2.3 Liquidity

A Current Ratio of 0.96 indicates that HBC may have some problems paying its short term obligations.

With a Current ratio value of 0.96, HBC is not doing good in the industry: 73.68% of the companies in the same industry are doing better.

HBC has a Quick Ratio of 0.96. This is a bad value and indicates that HBC is not financially healthy enough and could expect problems in meeting its short term obligations.

With a Quick ratio value of 0.59, HBC is not doing good in the industry: 80.26% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
Current Ratio	0.96
Quick Ratio	0.59

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

HBC shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -9.45%.

HBC shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 18.16%.

Measured over the past years, HBC shows a very strong growth in Revenue. The Revenue has been growing by 30.59% on average per year.

EPS 1Y (TTM)-9.45%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-43.56%

Revenue 1Y (TTM)18.16%

Revenue growth 3Y43.22%

Revenue growth 5Y30.59%

Sales Q2Q%-5.2%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for HBC. In the last year negative earnings were reported.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2YN/A

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

HBC does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

HOFSETH BIOCARE ASA

OSL:HBC (11/6/2025, 7:00:00 PM)

1.895

+0.01 (+0.26%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)N/A N/A

Earnings (Next)N/A N/A

Inst Owners34.27%

Inst Owner ChangeN/A

Ins Owners0.64%

Ins Owner ChangeN/A

Market Cap748.68M

Revenue(TTM)262.17M

Net Income(TTM)-137022000

AnalystsN/A

Price TargetN/A

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DP0%

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)N/A

PT rev (3m)N/A

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)N/A

EPS NY rev (3m)N/A

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	2.86
P/FCF	N/A
P/OCF	N/A
P/B	736.89
P/tB	N/A
EV/EBITDA	N/A

EPS(TTM)-0.33

EYN/A

EPS(NY)N/A

Fwd EYN/A

FCF(TTM)-0.11

FCFYN/A

OCF(TTM)-0.09

OCFYN/A

SpS0.66

BVpS0

TBVpS-0.1

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-35.39%
ROE	-13486.42%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	35.99%
FCFM	N/A

ROA(3y)-32.56%

ROA(5y)-30.06%

ROE(3y)-185.37%

ROE(5y)-136.87%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y128.49%

GM growth 5Y94.79%

F-Score4

Asset Turnover0.68

Health

		Industry Rank	Sector Rank
Debt/Equity	203.13
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	19.15%
Cap/Sales	2.87%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	0.96
Quick Ratio	0.59
Altman-Z	0.86

F-Score4

WACC8.45%

ROIC/WACCN/A

Cap/Depr(3y)35.77%

Cap/Depr(5y)87.88%

Cap/Sales(3y)7.85%

Cap/Sales(5y)29.06%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-9.45%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-43.56%

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)18.16%

Revenue growth 3Y43.22%

Revenue growth 5Y30.59%

Sales Q2Q%-5.2%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y7.37%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y-647.43%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-438.44%

OCF growth 3YN/A

OCF growth 5YN/A

HOFSETH BIOCARE ASA / HBC.OL FAQ

Can you provide the ChartMill fundamental rating for HOFSETH BIOCARE ASA?

ChartMill assigns a fundamental rating of 1 / 10 to HBC.OL.

What is the valuation status of HOFSETH BIOCARE ASA (HBC.OL) stock?

ChartMill assigns a valuation rating of 0 / 10 to HOFSETH BIOCARE ASA (HBC.OL). This can be considered as Overvalued.

How profitable is HOFSETH BIOCARE ASA (HBC.OL) stock?

HOFSETH BIOCARE ASA (HBC.OL) has a profitability rating of 1 / 10.

HOFSETH BIOCARE ASA (HBC.OL) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

HOFSETH BIOCARE ASA / HBC.OL FAQ

Can you provide the ChartMill fundamental rating for HOFSETH BIOCARE ASA?

What is the valuation status of HOFSETH BIOCARE ASA (HBC.OL) stock?

How profitable is HOFSETH BIOCARE ASA (HBC.OL) stock?